Latest Conference Content

When results from the EMPA-REG OUTCOME trial came out, nobody was expecting empagliflozin to have a particularly robust benefit on heart failure and several questions were raised as a result, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.

Results from the phase 3 EXPLORER-HCM trial show mavacamten may finally offer a therapeutic solution for patients with hypertrophic cardiomyopathy.

A new study shows that empagliflozin, the diabetes drug that set off a market frenzy 5 years ago, is on par with dapagliflozin for certain heart failure patients.

Through EVAPORATE, we've been able to show at 18 months that patients taking icosapent ethyl (Vascepa) have less plaque and that there is some atherosclerosis regression, marking mechanisms of benefit for these patients, said Matthew Budoff, MD, professor of medicine at the David Geffen School of Medicine at UCLA and investigator at The Lundquist Institute.

A new analysis from the REDUCE-IT trial finds that cardiovascular benefits of Vascepa are consistent no matter what type of statin a patient takes for cholesterol.

A study finds that too few of patients classified as very high risk under European criteria are meeting 2019 LDL cholesterol targets because they don't get enough medication.

According to the World Health Organization, self-care is “the ability of individuals, families, and communities to promote and maintain health, prevent disease, and cope with illness with or without the support of a health care provider.”

“We need to maintain our focus on key populations to ensure that we're focusing on each and every key population—from men who have sex with men to sex workers to people who inject drugs to our trans community—to make sure every single community has access to both prevention and treatment services and that we’re meeting each of the community members where they are to ensure that they can achieve viral suppression,” said Ambassador Deborah Birx, MD, on day 4 of AIDS 2020.

A panel of experts came together on day 3 of AIDS 2020 to discuss their experiences with telehealth during the first few months of the coronavirus disease 2019 (COVID-19) pandemic in attempting to not disrupt the continuum of care for their patients with HIV, those at risk for the virus, and their care teams, as well as to give advice moving forward in continuing to offer the service.

Individuals with severe mental illness are notoriously difficult to engage and retain in HIV care due to fragmented health care policies and systems that perpetuate stigma, according to an electronic poster presentation today at AIDS 2020.

“We find ourselves in a very unusual situation, and now is a good time for me to lay some common denominator principles that I think can be applicable to many, if not all, the countries beset with an HIV epidemic,” said Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, in a special live session on day 2 of AIDS 2020.

Higher rates of HIV can be seen within specific communities, particularly minority communities, along with a systematic bias taking place in policy and medical settings, noted Greg Millet, vice president at the Foundation for AIDS Research (amFAR) and director of amFAR’s Public Policy Office, on day 2 of AIDS 2020.

The US government's Ending the HIV Epidemic: A Plan for America, is founded on 4 pillars: diagnose, treat, prevent, respond. The goals of this program are to reduce new HIV infections by 75% by 2025 and by 90% by 2030.

Following implementation of several major provisions of the Affordable Care Act (ACA) in 2014, health insurance coverage for HIV-positive individuals increased, leading to sustained viral suppression in some instances and improving their ability to increase access to often life-saving services.

This year marks the 23rd International AIDS Conference, AIDS 2020, and the 30th anniversary of the first conference held in San Francisco in 1990 amid the first few years of the AIDS epidemic. The theme for this year’s conference is “Resilience,” and that certainly holds true for this global undertaking, which is happening in a virtual setting for the first time in the conference’s history due to the current coronavirus disease 2019 pandemic.

The coronavirus disease 2019 (COVID-19) pandemic will hopefully be a wakeup call to take diabetes more seriously and to work to prevent diabetes and its complications, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.

Peer support is a huge advantage of technological health interventions for teens with type 1 diabetes (T1D), while integrating technology with physical activities is important when promoting healthy lifestyles, said Tara Kaushal, MD, physician and clinical researcher at Joslin Diabetes Center.

During the National Association of Accountable Care Organizations Virtual 2020 Spring Conference, panelists discussed how data sharing can be implemented in health care systems and spur the evolution of population health management.

Technology has made it easier to deliver health care in the home in recent years, but the financing models have not caught up just yet.

Presented at AHIP’s Institute & Expo Online 2020, panelists discuss in a webinar how greater collaboration of health insurance providers with state and county leaders can ameliorate barriers to access to health care and promote timely interventions to improve health outcomes.

Panelists at the AHIP Institute & Expo Online discussed whether algorithms will play a greater role in the future in reallocating health care resources.

During AHIP’s Institute & Expo Online 2020, the conversation focused on the impact the pandemic has had on health coverage and what can be done to improve health equity, among other issues.

In a webinar presented at the AHIP Institute & Online Expo 2020, experts discussed how data analytics are addressing gaps in health care and providing timely, effective interventions.

New results from the Diabetes Prevention Program Outcomes Study (DPPOS), presented at the American Diabetes Association’s 80th Scientific Sessions, showed persistent reductions in type 2 diabetes (T2D) development over an average 22-year follow-up period.

New results from the Diabetes Prevention Program Outcomes Study (DPPOS), presented at the American Diabetes Association’s 80th Scientific Sessions, showed persistent reductions in type 2 diabetes (T2D) development over an average 22-year follow-up period.

During a session on telehealth at the National Association of ACOs (NAACOS) 2020 Virtual Spring Conference, viewers were told to look at the proposed 2021 Medicare Physician Fee Schedule when it is released next month to see which changes might become permanent even after the public health emergency ends.

Accelerating the shift to value-based care, as well as the growing presence of telehealth, may be potentially beneficial long-term effects of COVID-19 on the health care industry, said Dan Mendelson, MPP, founder of Avalere Health.

The light-hearted debate, “Primary Cardiovascular Prevention with SGLT2 Inhibitors or GLP-1 Receptor Agonists: Are We Ready for Prime Time?” took place Monday during the 80th American Diabetes Association Scientific Sessions.

A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.

Many in the endocrinology community still endorse using metformin first in patients with type 2 diabetes, but that isn’t really necessary any more now that sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, said Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center.